Alkermes (ALKS) Other Accumulated Expenses (2011 - 2026)
Alkermes (ALKS) posted quarterly Other Accumulated Expenses of $126.2 million for Q2 2026, up 40.23% year-over-year from $90.0 million in Q2 2025, and down 7.74% quarter-over-quarter from $136.8 million in Q1 2026.
Alkermes (ALKS) Other Accumulated Expenses (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Other Accumulated Expenses for 16 consecutive years, with $126.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Accumulated Expenses rose 40.23% year-over-year to $126.2 million; the TTM figure through Jun 2026 stood at $126.2 million (up 40.23% YoY), while the FY2025 annual figure was $99.2 million, up 44.26% from the prior year.
- Other Accumulated Expenses declined to $126.2 million in Q2 2026 per ALKS's latest filing, from $136.8 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $136.8 million in Q1 2026 and bottomed at $67.3 million in Q3 2024.
- Historically, Other Accumulated Expenses has averaged $95.1 million across 5 years, with a median of $91.4 million in 2022.
- Annual changes were most pronounced in 2024 — Other Accumulated Expenses dropped 25.12% — and 2026, when it soared 64.63%.
- Alkermes' Other Accumulated Expenses stood at $108.2 million in 2022, then fell by 15.12% to $91.8 million in 2023, then decreased by 25.12% to $68.7 million in 2024, then soared by 44.26% to $99.2 million in 2025, then rose by 27.27% to $126.2 million in 2026.
- Business Quant data shows ALKS's Other Accumulated Expenses at $126.2 million in Q2 2026, $136.8 million in Q1 2026, and $99.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 126.21 Mn |
| Mar 31, 2026 | 136.79 Mn |
| Dec 31, 2025 | 99.17 Mn |
| Sep 30, 2025 | 79.79 Mn |
| Jun 30, 2025 | 90.00 Mn |
| Mar 31, 2025 | 83.09 Mn |
| Dec 31, 2024 | 68.74 Mn |
| Sep 30, 2024 | 67.26 Mn |
| Jun 30, 2024 | 85.64 Mn |
| Mar 31, 2024 | 81.59 Mn |
| Dec 31, 2023 | 91.81 Mn |
| Sep 30, 2023 | 88.45 Mn |
| Jun 30, 2023 | 98.35 Mn |
| Mar 31, 2023 | 105.30 Mn |
| Dec 31, 2022 | 108.16 Mn |
| Sep 30, 2022 | 117.06 Mn |
| Jun 30, 2022 | 93.90 Mn |
| Mar 31, 2022 | 91.02 Mn |
| Dec 31, 2021 | 75.51 Mn |
| Sep 30, 2021 | 101.44 Mn |